Genitourinary System Carcinoma — Trials

Genitourinary System Carcinoma — Trials · CancerIndex

Clinical trials

Registered studies

4,919 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 1,501
Recruiting: 783
Ph III recruiting: 85
Growth YoY: +18.1%
Industry share: 27%
Top sponsor: National Cancer Institute (NCI)
Termination share: 37.6%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (758)

clinicaltrialsPublishedShowing 351–400 of 564 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05960578	Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study	active not recruiting	Phase 2	8	University of WashingtonOTHER	1	Apr 14, 2026	clinicaltrials
NCT03401788	A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004)	active not recruiting	Phase 2	50	Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY